Table 1 The correlation between the expression levels of SIRT7 and RND3 and the clinical features of bladder cancer.

Patients

126

37 (29.4)

89 (70.6)

85 (67.5)

41 (32.5)

Age (year)

0.54

0.395

 <63

56

18(48.6)

38(42.7)

40(47.1)

16(39.0)

 ≥ 63

70

19(51.4)

51(57.3)

45(52.9)

25(61.0)

Gender

0.93

0.061

 Male

105

31(83.8)

74(83.1)

75(88.2)

30(73.2)

 Female

21

6(16.2)

15(16.9)

10(11.8)

11(26.8)

BMI (kg/m²)

0.443

0.808

 <24

48

16(43.2)

32(36.0)

33(38.8)

15(36.6)

 ≥24

78

21(56.8)

57(64.0)

52(61.2)

26(63.4)

Smoking history

0.311

0.99

 Yes

80

21(56.8)

59(66.3)

54(63.5)

26(63.4)

 No

46

16(43.2)

30(33.7)

31(36.5)

15(36.6)

Chemotherapy protocol

0.962

0.818

 Cisplatin and Gemcitabine

119

35(94.6)

84(94.4)

80(94.1)

39(95.1)

 Carboplatin and Gemcitabine

7

2(5.4)

5(5.6)

5(5.9)

2(4.9)

T stage

<0.001

0.106

 T2

70

29(78.4)

41(46.1)

43(50.6)

27(65.9)

 T3/T4

56

8(21.6)

48(53.9)

42(49.4)

14(34.1)

Lymph node metastasis

0.01

0.516

 N0 / Nx

97

34(91.9)

63(70.8)

64(75.3)

33(80.5)

 N1 /N2

29

3(8.1)

26(29.2)

21(24.7)

8(19.5)

Vascular invasion

<0.001

0.006

 No

64

31(83.8)

33(37.1)

36(42.4)

28(68.3)

 Yes

62

6(16.2)

56(62.9)

49(57.6)

13(31.7)

Histological variant

0.388

0.664

 Pure urothelial

107

33(89.2)

74(83.1)

73(85.9)

34(82.9)

 Variant histology

19

4 (10.9)

15(16.9)

12(14.1)

7(17.1)